Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MFC-0102
- Development stage
- Preclinical
- Lead developer
- Medific
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
MFC-0102 is an investigational exosome-based therapeutic developed by Medific Co., Ltd. It is currently in preclinical development for the treatment of neoplasms (solid tumors) and digestive system disorders, with a specific focus on nonalcoholic steatohepatitis (NASH) and solid tumors. The precise mechanism of action, molecular targets, and detailed pharmacological properties have not been disclosed publicly as of June 2025. The drug represents a novel modality within the field of exosome therapeutics, which are being explored for their potential to deliver bioactive molecules to target tissues in various disease contexts[2].
Beyond the preview
Go deeper on MFC-0102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MFC-0102.